MTFB | tickerfilter.com

Fundamental analysis

61%

Profitability 50%

Dept financing 50%

Liquidity 75%

Performance 70%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$0.10

P/E Ratio

N/A

DAY RANGE

$0.10 - $0.10

EPS

-$0.80

52 WEEK RANGE

$0.08 - $11.49

52 WEEK CHANGE

-$98.27

MARKET CAP

2.548 M

YIELD

N/A

SHARES OUTSTANDING

24.267 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,409,219

AVERAGE 30 VOLUME

$970,397

Company detail

CEO: Graham George Lumsden
Region: US
Website: https://www.motifbio.com/
Employees: 0
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.

MTFB - Motif Bio Plc Sponsored ADR